Gonadorelin

What it is

Gonadorelin is the drug name for lab-made gonadotropin-releasing hormone (GnRH), also called luteinizing hormone-releasing hormone (LHRH or LH-RH). It is a chain of 10 amino acids identical to the GnRH made in the hypothalamus, the brain region that controls the pituitary gland¹²⁸. The hypothalamus releases GnRH in pulses. Each pulse makes the pituitary release luteinizing hormone (LH) and, less strongly, follicle-stimulating hormone (FSH), and these two hormones drive the testes and ovaries². In men, this pulsed signal keeps the testes making testosterone and sperm²⁹. Testosterone therapy turns the signal down, so the testes can shrink and make less sperm even while blood testosterone is normal²⁹. Some men on testosterone take gonadorelin hoping to prevent this⁶³⁰. The pattern matters. The approved pump labels used a pulse every 90 minutes, while continuous exposure ‘could temporarily reduce pituitary responsiveness’¹². In the blood, gonadorelin lasts only minutes². Kisspeptin works one step higher: it makes the brain release GnRH²⁹. GnRH analogs such as leuprolide (Lupron) and triptorelin are different molecules. Leuprolide’s label calls it ‘a synthetic nonapeptide analog’ of GnRH, a modified chain of nine amino acids, and ‘a long-acting GnRH analog’: one monthly injection causes ‘an initial stimulation followed by a prolonged suppression’ of LH and FSH³¹. The anti-doping list also keeps them apart: it names ‘GnRH, gonadorelin’ and then its ‘agonist analogues’, among them leuprorelin (leuprolide) and triptorelin²⁴. Studies of those analogs do not show what gonadorelin does.

FDA approved Factrel (gonadorelin hydrochloride) on 30 September 1982 as a new molecular entity¹⁸. Its label, from Ayerst Laboratories, described a single injection for testing how the pituitary responds¹³. Pulsed GnRH for women whose brains make too little of it was first approved in Europe, as Lutrelef, in 1983¹. In the US, Ferring’s Lutrepulse (gonadorelin acetate) received an orphan drug designation on 22 April 1987 and approval on 10 October 1989, and Canada approved it in 1993¹¹⁸³². Separately, a 1977 double-blind trial tested a lab-made LHRH nose spray in boys with undescended testes⁹.

Benefits: what the research shows

The strongest evidence is in people whose brains make too little GnRH. Ferring ran a randomized, double-blind trial in 39 women with primary hypothalamic amenorrhea (periods that never started because the brain makes too little GnRH); 24 sites, 22 in the US and 2 in Canada, randomized women from April 2014 to February 2018³. Counting the women treated for at least 14 days, pump pulses under the skin every 90 minutes, planned to run about 37 days, led to ovulation in 1 of 9, 4 of 9 and 5 of 9 women on 10, 15 and 20 µg, and in none of 10 on placebo¹³. The pooled 15 and 20 µg groups passed the trial’s main test (9 of 18 ovulated, one-sided p = 0.0120)³. Clinical pregnancy followed in 7 of 19 women on those doses and 0 of 10 on placebo (one-sided p = 0.0383, short of the p < 0.0130 the trial set for success)³. We found no journal report of the trial. Older open, non-randomized pump studies in 268 women, summarized in the Canadian label, reported ovulation in 94% (45 of 48) of women with primary and 96% (94 of 98) with secondary hypothalamic amenorrhea². Two other Ferring trials, in 132 and 350 women whose ovaries released eggs rarely or not at all, were completed in 2005 and 2010 but have no posted results³³³⁴. In men born with too little GnRH (congenital hypogonadotropic hypogonadism), an open-label, nonrandomized study of 28 men with no sperm, who chose their own treatment, found sperm appeared sooner with a gonadorelin pump than with hCG and hMG injections (median 6 vs 14 months, p = .01), while the share who made sperm (90% vs 83.3%) did not differ significantly³⁵. A 2021 review of 7 such studies (420 patients) linked pulsed GnRH with larger testes and earlier sperm production than hormone injections, but found no significant difference in sperm detection, sperm concentration or pregnancy rates; allergic reactions occurred mostly with GnRH, and the authors called for high-quality randomized trials³⁶. In boys with undescended testes, nose sprays of lab-made LHRH gave mixed results. A 1977 double-blind trial in 84 boys reported complete descent in 38% of 61 treated testes and a better position in another 28%; on placebo, 25% of 51 testes improved in position and 75% did not respond⁹. In a 1986 trial in 33 boys aged 1 to 5, testes descended in 3 of 16 (19%) on a GnRH spray and 1 of 17 (6%) on hCG injections (P = 0.23), and the authors judged both treatments ineffective in most cases³⁷. In a 1986 trial of 252 boys, 9% of LHRH-treated testes and 8% on placebo descended completely¹⁰. In a 1988 trial of 243 boys, hCG injections beat both the GnRH spray and placebo when both testes were undescended (p = 0.0009), and the authors did not support general use of the spray¹¹. In a 1992 trial of 141 boys, only six boys with both testes undescended had both reach the bottom of the scrotum, one of them on placebo (P = 0.12), and surgery could be avoided only in them³⁸. Counting testes rather than boys, the spray had an effect on at least one testis in 25% of boys with both testes undescended (P = 0.001), but none when one testis was undescended, and the authors wrote that LHRH ‘has a limited place’³⁸. A 1995 review that pooled randomized trials reported success in 21% with LHRH, 19% with hCG and 4% with placebo, and concluded that LHRH is effective but that data about the effect are ‘scanty’¹². In a 2022 open-label pilot study with no placebo or untreated comparison group, 7 men with Down syndrome were given pump pulses for 6 months. Their total score on a cognitive screening test rose in 6, and their reproductive hormones did not change apart from a slight fall in FSH³⁹. A placebo-controlled trial is recruiting⁴⁰. For the use it is mainly sold for, keeping the testes working in men on testosterone therapy, we found no trial: a PubMed search returned 24 papers and a ClinicalTrials.gov search 3 records, and none tested gonadorelin in such men⁴⁵. A 2026 review says GnRH therapy depends on pulsed delivery, is limited by the need for specialized infusion pumps, and ‘is currently reserved for specific clinical indications rather than routine management of TRT-induced reproductive suppression’²⁹.

Key human studies

Doses studied

Doses below are what studies used or what a label says. They are not advice, and gray-market products may not contain what their label says.

Half-life

About 2 to 10 minutes at first, then about 10 to 40 minutes²Initial and terminal half-lives of GnRH in blood after an injection into a vein or under the skin. The Canadian Lutrepulse monograph says they are similar in healthy volunteers and in men and women whose brains make too little GnRH, and similar for single injections and pump pulses. Kidney failure, but not liver disease, lengthens the half-life.

Routes

• Pump pulses under the skin, usually every 90 minutes (the Canadian label and recent trials; human data)
• Pump pulses into a vein (the original US Lutrepulse; human data)
• Single injection under the skin or into a vein (the Factrel pituitary test; human data)
• Nasal spray (trials in boys with undescended testes; human data)
• Skin patch driven by a small electric current (one completed trial in women; no results posted)
• Injections under the skin a few times a week (the pattern reported for men on testosterone; we found no trial data)

Every dose studied for Gonadorelin, with sources →

Legal status

United States

FDA approved two gonadorelin drugs for people, and Drugs@FDA lists both as discontinued: Factrel (gonadorelin hydrochloride, NDA 018123), approved 30 September 1982 and now listed under Hikma, and the Lutrepulse Kit (gonadorelin acetate, NDA 019687), approved 10 October 1989 and held by Ferring. openFDA lists no other gonadorelin application¹⁸. Factrel was a single injection for testing the pituitary¹³. Lutrepulse was given in pulses by a pump¹. Its orphan designation was for inducing ovulation in women with hypothalamic amenorrhea caused by too little GnRH or the wrong pulse pattern³². Ferring wrote in its 2017 trial protocol that Lutrepulse ‘was later withdrawn from the market for commercial reasons’, leaving no approved GnRH product in the US for that use¹. We found no source giving a reason for Factrel’s discontinuation, and gonadorelin is not on FDA’s list of drugs withdrawn for safety or effectiveness reasons⁴⁴. Ferring tested a pump version in the US and Canada from 2014 to 2018³. It registered another US study in 2025 and withdrew it before enrolling anyone, stating that ‘The decision to terminate development activities was based on business needs and unrelated to any safety or efficacy concerns’⁴⁵. Gonadorelin injections remain approved for cattle, and federal law restricts them to use by or on the order of a licensed veterinarian¹⁹. All five gonadorelin labels on DailyMed, the US label library, are animal drugs, among them a Zoetis product sold as Factrel⁴⁶. In a 17 June 2026 warning letter, FDA told an online seller that its ‘Gonadorelin’ was an unapproved new drug, after reviewing the seller’s website in May 2026. The letter says labels such as ‘RESEARCH USE ONLY’ and ‘not for human consumption’ did not change that the products were intended for human use²³. Gonadorelin is not a federally controlled substance⁴⁷.

US pharmacies

Gonadorelin is not in any of FDA’s 503A nomination categories (list updated 14 May 2026), is not on FDA’s list of bulk substances that may pose significant safety risks (page current 22 April 2026), and is not on FDA’s list of drugs withdrawn for safety or effectiveness reasons, which pharmacies may not compound⁴¹⁴²⁴⁴. That alone does not block compounding. Under 503A, a pharmacy must use a bulk ingredient that meets a USP or NF monograph if one exists. If none exists, it may use a component of an FDA-approved drug, or else a substance on FDA’s 503A bulks list. The powder also needs a valid certificate of analysis and an FDA-registered maker²¹. USP publishes a monograph for gonadorelin acetate, last revised in 2025²². FDA’s 503B list (updated 21 March 2025) marks ‘Gonadorelin Acetate’ with ‘**’, its flag for ‘components of FDA approved drugs’, and places it in Category 1, ‘Bulk Drug Substances Under Evaluation’, for outsourcing facilities²⁰. A footnote on that list says outsourcing facilities generally may not make essentially a copy of an approved drug, but FDA does not intend to act when they fill orders for a copy of an approved drug that has been discontinued and is no longer marketed²⁰. Our reading is that US pharmacies can lawfully compound gonadorelin on prescription through the monograph route, because a USP monograph for gonadorelin acetate exists²¹²². We found no gonadorelin-specific 503A statement from FDA. Pharmacies do make it: three recalls in 2022 covered pharmacy-made gonadorelin injections²⁷. The rules also explain part of the demand. hCG, which is widely used to protect the testes during testosterone therapy²⁹, has been regulated as a biological product since 23 March 2020, when FDA deemed its approved drug applications to be biologics licenses⁷, and FDA says biological products are not eligible for the compounding exemptions⁸. Gonadorelin, at 10 amino acids, is far below the 40-amino-acid line above which FDA counts a chain as a protein, so that change does not apply to it⁴⁸.

Other countries

Canada: gonadorelin and its salts are on Health Canada’s Prescription Drug List, with an entry effective 19 December 2013⁴⁹. Health Canada’s drug database lists 7 human gonadorelin products, none marketed: Factrel and Relisorm products canceled between 1996 and 2019, Lutrepulse 0.8 mg canceled on 24 December 2024 and Lutrepulse dormant since 21 April 2017. It also lists 8 veterinary gonadorelin products, 5 of them marketed, and Gonavet, a marketed veterinary product of an altered form that Health Canada lists as gonadorelin [6-D-Phe] acetate⁵⁰. Ferring’s 2017 protocol says Lutrelef with a wearable pump was approved in France (2009), the Netherlands (2010) and Germany (2011) for men and women with GnRH deficiency, and re-introduced in Canada in 2012¹. Australia: Schedule 4 (prescription-only medicine) in the Poisons Standard in force from 1 October 2026⁴³. UK and current EU status: not verified.

Sport

Prohibited at all times, in and out of competition, for male athletes. The 2026 List names ‘gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues’ under S2.2.1, testosterone-stimulating peptides in males, a non-Specified class²⁴. The 2027 List, in force from 1 January 2027, keeps the same wording²⁵. WADA’s 2026 and 2027 monitoring programs track ‘Gonadotrophin-releasing hormone (GnRH) analogues in females under 18 years only’; they do not say whether that includes gonadorelin itself⁵¹⁵².

Gonadorelin in the legal tracker →

Quality and the gray market

What testing finds

We found no independent lab tests of gonadorelin products. Finnrick, a service that publishes lab results for peptide samples, listed 11,999 tests of 34 products as of 25 September 2026, and none were of gonadorelin²⁶. FDA’s recall records list three Class II recalls of gonadorelin injections, all started in March 2022 and all for sterility. A Kentucky compounder recalled 294 vials of 100 µg/mL for ‘Lack of Assurance of Sterility’, and a Florida pharmacy recalled 6,017 and 1,843 vials of 0.2 mg/mL for ‘Lack of sterility assurance’²⁷. USP’s standard for gonadorelin acetate, revised in 2025, describes the powder as gonadorelin with unspecified amounts of acetic acid and water, and requires 95% to 105% gonadorelin once those are excluded²².

How it is sold

Sold online as ‘research’ powder. FDA’s 2026 warning letter quotes one seller’s product page: ‘Spermatogenesis Research: Investigations show how gonadorelin affects testosterone production and supports testes function in experimental subjects’²³. It is also prescribed as a compounded drug. A compounding pharmacy wrote in 2024 that some providers prescribe it ‘often as part of a testosterone replacement therapy (TRT) protocol’, which it said may be partly due to a regulatory change that ended compounded hCG⁶. The only study that article cites compared a gonadorelin pump with hCG and hMG injections in men born with too little GnRH, not in men on testosterone⁶³⁵. A peptide-information website that publishes a gonadorelin-versus-hCG article for men on testosterone says the community schedule does not reproduce the pump pattern of the trials, and that no controlled study has evaluated it³⁰. We did not find verified price or demand data.

Side effects and risks

• Untested use: we found no published trial of gonadorelin in men on testosterone therapy, so whether injections a few times a week protect the testes, and what they do over months, is unknown⁴⁵.
• The wrong pattern can suppress instead of stimulate. Continuous exposure ‘could temporarily reduce pituitary responsiveness’, and Factrel’s label warned that repetitive, high doses may cause ‘inhibition of spermatogenesis’, meaning less sperm production²¹³.
• Allergic reactions: Factrel’s label lists rare hypersensitivity and anaphylactic reactions after repeated doses, and case reports describe anaphylaxis and allergic reactions to GnRH given into a vein¹³¹⁴¹⁵. About 3% of patients given Factrel under the skin made antibodies to it, sometimes with a weaker effect².
• Pituitary tumors: bleeding into a pituitary tumor (pituitary apoplexy) has followed single test doses, in one case with sudden blindness¹³¹⁶¹⁷.
• Side effects on Factrel’s label include headache, light-headedness, nausea, abdominal discomfort, flushing and swelling at the injection site¹³. Pump use can cause inflammation, infection, mild vein inflammation (phlebitis) or a blood collection (hematoma) where the catheter entered².
• In women treated for infertility, 12% of pregnancies with delivery data were twins or triplets, and overstimulated ovaries were reported in under 1% of cases².
• Product quality: pharmacy-made injections have been recalled for lack of sterility assurance, and we found no independent tests of ‘research’ vials²⁶²⁷.
• Anti-doping: banned at all times for male athletes²⁴.

Documented harms

• Sep 1987A case report described anaphylaxis, a severe allergic reaction, in a patient given lab-made LH-RH by IV infusion; skin tests confirmed an allergic (IgE-mediated) reaction¹⁴.
• Mar 1988Two men with low reproductive hormones caused by disease above the pituitary had allergic reactions to GnRH given into a vein after earlier low-dose pulsed treatment under the skin¹⁵.
• Jan 1993A 54-year-old man with a large pituitary tumor developed headache and vomiting 20 minutes after a single 100 µg injection of GnRH, and was found blind and disoriented 5 hours later. A CT scan showed a large tumor with a dead center, consistent with pituitary apoplexy, and surgeons removed dead, bloody tissue¹⁶.
• Aug 2001A 56-year-old man with a prolactin-producing pituitary tumor had severe headache, loss of part of his field of vision and facial nerve palsy shortly after an LH-RH test. MRI showed bleeding in the tumor, and he improved dramatically after surgery¹⁷.
• 7 Mar 2022A Kentucky compounder began a recall of 294 vials of gonadorelin 100 µg/mL, distributed nationwide, for lack of sterility assurance; FDA classified it as Class II²⁷.
• 23 Mar 2022A Florida pharmacy began recalls of 6,017 and 1,843 vials of gonadorelin 0.2 mg/mL, distributed nationwide, for lack of sterility assurance; FDA classified them as Class II and lists them as ended on 5 October 2023²⁷.

Questions people ask

What is still unknown

• We found no trial of gonadorelin in men on testosterone therapy, so whether injections a few times a week preserve testicular size, sperm production or fertility is unknown.
• Why Factrel was discontinued: Drugs@FDA gives no reason, and we found no FDA notice saying whether it was withdrawn for safety or effectiveness reasons.
• When USP’s 2025 revision of its gonadorelin acetate monograph took effect: we could not open USP’s own site to check.
• We found no gonadorelin-specific 503A statement from FDA; the compounding conclusion rests on USP’s gonadorelin acetate monograph and FDA’s general 503A rules.
• Results of two completed Ferring trials (NCT00296465, 132 women; NCT00796289, 350 women) are not posted, and we found no journal report of NCT01976728.
• The nasal-spray trials in boys call the drug LHRH or GnRH; their abstracts do not name the product.
• No independent lab tests of ‘research’ or compounded gonadorelin vials were found.
• UK and current EU status were not verified, and the European approvals Ferring describes were not checked against European registers.
• WADA’s monitoring programs track ‘GnRH analogues’ in females under 18; whether gonadorelin itself is included is not stated.
• A placebo-controlled trial of pump GnRH for cognition in Down syndrome (NCT04390646) is recruiting, with an estimated completion in December 2028.
• A consumer drug-information page says ‘generic versions may be available’ of Factrel, but Drugs@FDA lists no gonadorelin application for people other than the two discontinued ones.

Sources

1. 1A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump: clinical trial protocol, amendment 7 (NCT01976728) Ferring Pharmaceuticals, via ClinicalTrials.gov, 6 Dec 2017. cdn.clinicaltrials.gov
2. 2LUTREPULSE (gonadorelin acetate) product monograph Ferring Inc. via Health Canada Drug Product Database, 17 May 2016. pdf.hres.ca
3. 3LutrePulse Hypogonadotropic Hypogonadism (NCT01976728), registry record with results ClinicalTrials.gov, 3 Mar 2021. clinicaltrials.gov
4. 4PubMed search: gonadorelin with testosterone or TRT in the title or abstract (24 results; none gave gonadorelin to men taking testosterone) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov
5. 5ClinicalTrials.gov search for ‘gonadorelin AND “testosterone replacement”’ (3 records, none giving gonadorelin to men on testosterone) ClinicalTrials.gov, accessed 8 Oct 2026. clinicaltrials.gov
6. 6Compounded Gonadorelin in Men’s Health Empower Pharmacy (vendor), 7 Mar 2024. empowerpharmacy.com (seller page, deliberately not linked)
7. 7List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020 U.S. Food and Drug Administration, accessed 8 Oct 2026. fda.gov
8. 8Compounding and the FDA: Questions and Answers U.S. Food and Drug Administration, 16 Sep 2025. fda.gov
9. 9Treatment of cryptorchidism by intranasal synthetic luteinising-hormone releasing hormone. Results of a collaborative double-blind study Lancet, 10 Sep 1977. pubmed.ncbi.nlm.nih.gov
10. 10Double-blind, placebo-controlled study of luteinising-hormone-releasing-hormone nasal spray in treatment of undescended testes Lancet, 19 Apr 1986. pubmed.ncbi.nlm.nih.gov
11. 11Treatment of cryptorchidism with human chorionic gonadotropin or gonadotropin releasing hormone. A double-blind controlled study of 243 boys Hormone Research, 1988. pubmed.ncbi.nlm.nih.gov
12. 12A review and meta-analysis of hormonal treatment of cryptorchidism Journal of Clinical Endocrinology and Metabolism, Sep 1995. pubmed.ncbi.nlm.nih.gov
13. 13Factrel (Gonadorelin): Side Effects, Uses, Dosage, Interactions, Warnings RxList, 8 Aug 2022. rxlist.com
14. 14Anaphylactic reaction to synthetic luteinizing hormone-releasing hormone Fertility and Sterility, Sep 1987. pubmed.ncbi.nlm.nih.gov
15. 15Hypersensitivity reaction with intravenous GnRH after pulsatile subcutaneous GnRH treatment in male hypogonadotrophic hypogonadism Postgraduate Medical Journal, Mar 1988. pubmed.ncbi.nlm.nih.gov
16. 16Pituitary apoplexy and sudden blindness following the administration of gonadotrophin releasing hormone Clinical Endocrinology, Jan 1993. pubmed.ncbi.nlm.nih.gov
17. 17Pituitary apoplexy caused by luteinizing hormone-releasing hormone in prolactin-producing adenoma Internal Medicine, Aug 2001. pubmed.ncbi.nlm.nih.gov
18. 18Drugs@FDA via openFDA: applications containing gonadorelin (NDA 018123 Factrel, NDA 019687 Lutrepulse) U.S. Food and Drug Administration (openFDA), 7 Oct 2026. api.fda.gov · data query
19. 1921 CFR 522.1077, Gonadorelin (eCFR, as of 5 October 2026) Electronic Code of Federal Regulations (eCFR), 5 Oct 2026. ecfr.gov
20. 20Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 21 Mar 2025. fda.gov
21. 21Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act U.S. Food and Drug Administration, 14 May 2026. fda.gov
22. 22USP Monographs: Gonadorelin Acetate (USP-NF, 2025 revision) United States Pharmacopeia, 2025. doi.usp.org
23. 23Warning letter to Wholesale Peptide (MARCS-CMS 729447) U.S. Food and Drug Administration, 17 Jun 2026. fda.gov
24. 24World Anti-Doping Code International Standard: Prohibited List 2026 World Anti-Doping Agency, 24 Sep 2025. wada-ama.org
25. 25World Anti-Doping Code International Standard: Prohibited List 2027 World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
26. 26Finnrick public data summary (llms-full.txt, generated 25 September 2026) Finnrick, 25 Sep 2026. finnrick.com
27. 27FDA drug recall (enforcement report) records for products described as gonadorelin, via the openFDA drug/enforcement API (3 records) U.S. Food and Drug Administration (openFDA), 30 Sep 2026. api.fda.gov · data query
28. 28Gonadorelin (CID 638793) PubChem, National Library of Medicine, accessed 8 Oct 2026. pubchem.ncbi.nlm.nih.gov
29. 29Emerging peptide and neuroendocrine strategies for TRT-induced reproductive suppression and functional male hypogonadism: a narrative review Frontiers in Reproductive Health, 2026. pubmed.ncbi.nlm.nih.gov
30. 30Gonadorelin: How It Works, Mechanism & Evidence (2026) The Peptide Catalog, 30 Jul 2026. thepeptidecatalog.com
31. 31LUPRON DEPOT 3.75 mg (leuprolide acetate for depot suspension) prescribing information AbbVie Inc. via DailyMed (U.S. National Library of Medicine), 22 Sep 2025. dailymed.nlm.nih.gov
32. 32Orphan drug designation: gonadorelin acetate (Lutrepulse) for induction of ovulation in women with hypothalamic amenorrhea U.S. Food and Drug Administration, Office of Orphan Products Development, 22 Apr 1987. accessdata.fda.gov
33. 33A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH (NCT00296465) ClinicalTrials.gov, 19 May 2011. clinicaltrials.gov
34. 34Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females (NCT00796289) ClinicalTrials.gov, 9 Sep 2015. clinicaltrials.gov
35. 35The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men American Journal of Men’s Health, 2019. pubmed.ncbi.nlm.nih.gov
36. 36Spermatogenesis of Male Patients with Congenital Hypogonadotropic Hypogonadism Receiving Pulsatile Gonadotropin-Releasing Hormone Therapy Versus Gonadotropin Therapy: A Systematic Review and Meta-Analysis World Journal of Men’s Health, Oct 2021. pubmed.ncbi.nlm.nih.gov
37. 37Hormonal therapy of cryptorchidism. A randomized, double-blind study comparing human chorionic gonadotropin and gonadotropin-releasing hormone New England Journal of Medicine, 20 Feb 1986. pubmed.ncbi.nlm.nih.gov
38. 38Management of the non-descended testis: doubtful value of luteinizing-hormone-releasing-hormone (LHRH). A double-blind, placebo-controlled multicentre study International Journal of Andrology, Apr 1992. pubmed.ncbi.nlm.nih.gov
39. 39GnRH replacement rescues cognition in Down syndrome Science, 2 Sep 2022. pubmed.ncbi.nlm.nih.gov
40. 40GnRH Therapy on Cognition in Down Syndrome (NCT04390646) ClinicalTrials.gov, 12 Feb 2024. clinicaltrials.gov
41. 41Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
42. 42Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration, 22 Apr 2026. fda.gov
43. 43Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327) Federal Register of Legislation, Australian Government, 28 Sep 2026. legislation.gov.au
44. 4421 CFR 216.24, Drug products withdrawn or removed from the market for reasons of safety or effectiveness (eCFR, as of 5 October 2026) Electronic Code of Federal Regulations (eCFR), 5 Oct 2026. ecfr.gov
45. 45A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump (NCT07152730) ClinicalTrials.gov, 14 Nov 2025. clinicaltrials.gov
46. 46DailyMed label search: gonadorelin (5 results, all animal drugs) DailyMed (U.S. National Library of Medicine), accessed 8 Oct 2026. dailymed.nlm.nih.gov
47. 4721 CFR Part 1308, Schedules of Controlled Substances (eCFR, as of 25 September 2026) Electronic Code of Federal Regulations (eCFR), 25 Sep 2026. ecfr.gov
48. 48Definition of the Term “Biological Product” (final rule, 85 FR 10057) Federal Register, 21 Feb 2020. federalregister.gov
49. 49Prescription Drug List: Human Use Health Canada (Drug and Health Product Register), accessed 8 Oct 2026. hpr-rps.hres.ca
50. 50Drug Product Database API: active ingredient search for gonadorelin (16 products; status checked in each product record) Health Canada, accessed 8 Oct 2026. health-products.canada.ca · data query
51. 51The 2026 Monitoring Program World Anti-Doping Agency, Sep 2025. wada-ama.org
52. 52The 2027 Monitoring Program World Anti-Doping Agency, 21 Sep 2026. wada-ama.org